Isnafab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the effective management of gastroesophageal reflux disease (GERD), acid reflux, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, providing symptomatic relief from acid-related damage and promoting mucosal healing. The synergistic action of these two agents addresses both the underlying hyperacidity and impaired gastric motility often observed in GERD and dyspepsia. Isnafab-DSR is indicated for patients requiring both acid suppression and prokinetic therapy, enhancing overall therapeutic outcomes. It is typically administered orally once daily, preferably before meals, under medical supervision. Caution is advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. Consultation with a healthcare professional is essential prior to initiation to ensure appropriate use and monitoring.